Table S1.
Bibliography of validated administrative data, diagnoses, treatments, and examinations in the Danish National Patient Registry
| ICD codesa | Condition | Study period (contact type; diagnosis type) | ICD codes/algorithmb | nc | PPV; NPV; sensitivity; specificityd | Reference standard | Reference |
|---|---|---|---|---|---|---|---|
| Administrative data | |||||||
| Acute medical admission | 2009 (IN) | Acute | 127 | PPV =97.6 (93.3–99.2); NPV =90.3 (75.1–96.7); Se =97.6 (93.3–99.2); Sp =90.3 (75.1–96.7) | MR | Vest-Hansen B et al. Clin Epidemiol. 201352 | |
| Nonacute medical admission | 2009 (IN) | Nonacute | 31 | PPV =90.3 (75.1–96.7); NPV =97.6 (93.3–99.2); Se =90.3 (75.1–96.7); Sp =97.6 (93.3–99.2) | MR | Vest-Hansen B et al. Clin Epidemiol. 201352 | |
| Diagnoses | |||||||
| A00–B99: Certain infectious and parasitic diseases | |||||||
| A02 | Infections among patients diagnosed with cancer within previous 5 y (excl non-melanoma skin cancer) | 2006–2010 (IN; A) | A02.1, A02.2C, A15–A19, A20.3, A22.7, A26.7, A42.7, A28.2B, A31, A32.1, A32.7, A39.0, A40–41, A46, A49.9, A54.8D, A54.8G, A87, B00.3, B01.0, B02.1, B26.1, B35–B49, B05.1, G00–G05, H01.0, H03, H60.0, H60.1–H60.3, H62, I33, I39.8, J12–J18, K12.2, K13.0, K61, L01, L03, L08, M00, M01.1, M01.3, M72.6, M86, N10–N12, N15.1, N15.9, N30, N34, N39.0 | 266 | PPV =98.1 (95.7–99.2) overall, 80.1 (75.0–84.5) for agreement of specific infection type, 79.0 (63.7–88.9) for skin infection, 92.5 (85.3–96.3) for pneumonia, 84.4 (71.2–92.3) for sepsis | MR | Holland-Bill L et al. Ann Epidemiol. 201453 |
| A39 | Meningococcal disease | 1980–1993 (IN; A/Be) | 036.09, 036.10, 036.11, 036.12, 036.18, 036.19, 036.89, 036.99 | 296 | PPV =85.8 (81.4–89.3); Se =89.8 (85.7–92.8) | MR (ref for PPV); Notification system for communicable diseases and DNPR (ref for Se) | Sørensen HT et al. Int J Risk Saf Med. 199554 |
| A40 | Septicemia | 1994 (IN; A/Be) | A02.1, A28.2, A40–41, A42.7, A54.8, O08.0, O75.3, O85.9, P36 | 83 | PPV =21.7 (14.2–31.7); Se =4.4 (2.8–6.9) | MR; Bacteremia database | Madsen KM et al. Infect Control Hosp Epidemiol. 199825 |
| Bacteremia | 2000–2011 (IN; A/Be) | Definite (A02.1, A28.2B, A32.7, A39.2–4, A40–1, A42.7, A49.9A, B37.7, B49.9A) or possible (predominantly, A01.0, A39.0, A41.9, A46.9, I38.9, P36, P37.5, N10.9, N30.0, N39.0, O08.0U, O08.0V, KTJA40, KTJWC00, KTJL10) | 37,740 | SeDefinite/possible =64.9 (64.5–65.3) SeDefinite =32.3 (31.9–32.7) |
Microbiology results recorded in electronic laboratory information system | Gradel KO et al. Plos One. 201555 | |
| A41 | Gram-negative bacteremia | 1994–2012 (IN; A/B) | A41.5, A41.9B (septicemia/sepsis due to other Gram-negative organisms or urosepsis) | 100 | PPVAll =72.0 (62.5–79.9); PPVA41.5 =85.7 (74.3–92.6); PPVA41.9B =54.6 (40.1–68.3) | Microbiology results recorded in electronic laboratory information system | Søgaard KK et al. Clin Epidemiol. 201456 |
| B18.0 | HBV in HIV patients | 1995–2004 (IN/OUT; A/Be) | B18.0–B18.1 | 47 | PPV =63.8 (49.5–76.0); Se =23.3 (16.8–31.3) | Danish HIV Cohort Study | Obel N et al. BMC Med Res Methodol. 200857 |
| B18.2 | HCV in HIV patients | 1995–2004 (IN/OUT; A/Be) | B18.2 | 134 | PPV =94.0 (88.7–96.9); Se =47.7 (41.8–53.7) | Danish HIV Cohort Study | Obel N et al. BMC Med Res Methodol. 200857 |
| B20 | HIV | 1995–2004 (IN/OUT; A/Be) | B20–B24 | n/a (≥2006) | Se =98.7 (98.1–99.1) | Danish HIV Cohort Study | Obel N et al. BMC Med Res Methodol. 200857 |
| B21 | AIDS | 1998–2007 (IN/OUT; A) | B21–B24 | 50 | PPV =100 (92.9–100) | DS | Thygesen SK et al. BMC Med Res Methodol. 201158 |
| C00–D48: Neoplasms | |||||||
| C00–C75 | Any tumor | 1998–2007 (IN/OUT; A) | C00–C75 | 50 | PPV =98.0 (89.4–99.9) | DS | Thygesen SK et al. BMC Med Res Methodol. 201158 |
| 1977 (IN; A/B) | 140–239 (excl brain tumors and non-melanoma skin cancer) | 17,956 | PPV =91.7 (91.3–92.1); Se =75.8 (75.2–76.3) | DCR | Osterlind A et al. Ugeskr Laeger. 198559 | ||
| C18 | Colorectal cancer | 2001–2006 (IN/OUT;e A/Be) | C18–20 | 24,153 | PPV =88.9 (88.5–89.3); Se =93.4 (93.1–93.7) | DCR | Helqvist L et al. Eur J Cancer Care. 201260 |
| Colorectal cancer recurrences | 2001–2011 (IN/OUT/ED;e A/Be) | C76–C80, C18.9X, C20.9X, BWHA1–2, BOHJ17, BOHJ19B1 (algorithm combining metastasis and chemotherapy codes in the DNPR with cancer recurrence codes in the PD) | 70 | PPV =85.7 (75.7–92.1); NPV =99.0 (97.0–100); Se =95.2 (86.9–98.4); Sp =96.6 (93.8–98.1) | Actively followed cohort | Lash TL et al. Int J Cancer. 201461 | |
| C51–58 | Gynecological cancers | 1977–1988 (IN; A/Be) | 180, 182.0, 183 (among women undergoing gynecological surgery) | 614 | PPV =89.9 (87.3–92.0); Se =94.7 (92.6–96.2) | MR | Kjaergaard J et al. J Epidemiol Biostat. 200162 |
| C53 | Cervical cancer | 1977–1988 (IN; A/Be) | 180 (among women undergoing gynecological surgery) | 148 | PPV =88.5 (82.4–92.7); Se =94.2 (89.1–97.1) | MR | Kjaergaard J et al. J Epidemiol Biostat. 200162 |
| C54–55 | Uterus cancer | 1977–1988 (IN; A/Be) | 182.00–182.09 (among women undergoing gynecological surgery) | 261 | PPV =90.4 (86.2–93.4); Se =92.9 (89.1–95.5) | MR | Kjaergaard J et al. J Epidemiol Biostat. 200162 |
| C56 | Ovarian cancer | 1977–1988 (IN; A/Be) | 183 | 205 | PPV =90.2 (85.4–93.6); Se =97.4 (94.0–98.9) | MR | Kjaergaard J et al. J Epidemiol Biostat. 200162 |
| C61 | Prostate cancer | 1995–2012 (IN/OUT; A/B) | C61 | 240 | PPV =98.3 (95.8–99.4) | MR (histologically-/biopsy-verified) | Drljevic A et al. Clin Epidemiol 201463 |
| C64 | Urological cancer | 2004–2009 (IN/OUT; A/Be) | C64–68, D09.0–D09.1, D30.1–D30.9, D41.1–D41.9 | 41,129 | PPV =86.6 (86.3–86.9); Se =94.9 (94.7–95.2) | DCR | Gammelager H et al. Eur J Cancer Prev 201264 |
| C76–80 | Metastatic solid tumor | 1998–2007 (IN/OUT; A) | C76–C80 | 50 | PPV =100 (92.9–100) | DS | Thygesen SK et al. BMC Med Res Methodol. 201158 |
| C79.5 | Bone metastases or skeletal-related events in patients with prostate (P) or breast (B) cancer | 2000–2005 (n/a; n/a) | C79.5, BWGC1, M80.0, M84.4, M90.7, M43.9, 48.5, M54.5, M54.6, M54.9, G95.2, G95.8, KNAG (+ C61.9/C50) | 27 P; 15 B | PPVP =92.6 (76.6–97.9); NPVP =71.2 (60.0–80.4); PPVB =73.3 (48.1–89.1); NPVB =90.6 (82.5–95.2); SeP =54.4 (40.2–67.9); SpP =96.3 (87.5–99.0); SeB =57.9 (36.3–76.9); SpB =95.1 (88.0–98.1) | MR | Jensen AØ et al. Clin Epidemiol. 200965 |
| C79.5 | Bone metastases in patients with prostate cancer | 2005–2010 (IN/OUT;e A/Be) | C61 (from DCR) with prespecified PSA values, antiresorptive therapy, and bone scintigraphy, but without C77–C79 | 212 | PPVPSA >50 μg/L =9.6 (4.7–18.5) and NPVPSA <50 μg/L =98.6 (94.9–99.6) regardless of receipt of antiresorptive therapy or presence of bone scintigraphy | MR | Ehrenstein V et al. Clin Epidemiol. 201566 |
| C81.0–96.9 | Hematological cancer | 1994–1999 (IN;e Ae) | C81.0–C96.9 | 1,075 | PPV =84.5 (82.2–86.5); Se =91.5 (89.6–93.1) | DCR | Nørgaard M et al. Eur J Cancer Prev. 200567 |
| C81 | Lymphoma | 1998–2007 (IN/OUT; A) | C81–C85, C88, C90, C96 | 50 | PPV =100 (92.9–100) | DS | Thygesen SK et al. BMC Med Res Methodol. 201158 |
| C81 | Hodgkin’s disease | 1994–1999 (IN;e Ae) | C81.0–9 | 77 | PPV =71.4 (60.5–80.3); Se =88.7 (78.5–94.4) | DCR | Nørgaard M et al. Eur J Cancer Prev. 200567 |
| C82 | Non-Hodgkin’s lymphoma or chronic lymphocytic leukemia | 1994–1999 (IN;e Ae) | C82.0–85.9, C88.0–9, C91.1, C96.0–9 | 613 | PPV =85.3 (82.3–87.9); Se =88.2 (85.3–90.6) | DCR | Nørgaard M et al. Eur J Cancer Prev. 200567 |
| C90 | Multiple myeloma and other malignant plasma cell neoplasms | 1994–1999 (IN;e Ae) | C90.0–2 | 158 | PPV =82.3 (75.6–87.4); Se =90.9 (85.1–94.6) | DCR | Nørgaard M et al. Eur J Cancer Prev. 200567 |
| C91 | Leukemia | 1998–2007 (IN/OUT; A) | C91–C95 | 50 | PPV =100 (92.9–100) | DS | Thygesen SK et al. BMC Med Res Methodol. 201158 |
| C92 | Acute myeloid leukemia | 1994–1999 (IN;e Ae) | C92.0 | 108 | PPV =67.6 (58.3–75.7); Se =89.0 (80.4–94.1) | DCR | Nørgaard M et al. Eur J Cancer Prev. 200567 |
| D25 | Uterine fibroma | 1977–1988 (IN; A/B) | 218.99 (among women undergoing gynecological surgery) | 1,430 | PPV =92.9 (91.4–94.1); NPV =88.9 (87.8–89.9); Se =77.4 (75.4–79.4); Sp =96.8 (96.2–97.4) | DS | Kjaergaard J et al. J Clin Epidemiol. 200268 |
| D27 | Benign ovarian neoplasms | 1977–1988 (IN; A/B) | 220.99 (among women undergoing gynecological surgery) | 743 | PPV =78.2 (75.1–81.0); NPV =90.0 (89.1–90.9); Se =58.3 (55.2–61.3); Sp =95.9 (95.2–96.5) | DS | Kjaergaard J et al. J Clin Epidemiol. 200268 |
| D35.3 | Craniopharyngioma | 1985–2004 (IN/OUT;e A/Be) | 194.39, 226.21, 226.29, 253.99; D35.3, D44.4, C75.2 | 607 | PPV =30.5 (27.0–34.3); Se =95.2 (77.3–99.2) | MR (for PPV)/Se with ref to North Jutland County registry and registries of a Danish neuroendocrine center | Nielsen EH et al. J Clin Epidemiol. 201169 |
| D47.2 | Monoclonal gammopathy | 2001–2011 (IN/OUT;e A/Be) | D47.2 | 327 | PPV =82.3 (77.8–86.0); Se =16.8 (14.4–19.6) | MR (for PPV); Se with ref to Regional monoclonal gammopathy database | Gregersen H et al. Clin Epidemiol. 201370 |
| D50–D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | |||||||
| D35.0A | Pheochromocytoma | 1977–1981 (IN; A/B) | 255.29 | 230 | PPV =19.1 (14.6–24.7) | MR | Andersen GS et al. Ugeskr Laeger. 198671 |
| D50.0 | Anemia caused by bleeding | 2000–2009 (IN/OUT; A/Be) | D50.0, D62.6 | 3,391 | PPV =95.4 (94.6–96.0) | LABKA | Zalfani J et al. Clin Epidemiol. 201272 |
| D51 | Anemia caused by B12 deficiency | 2000–2009 (IN/OUT; A/Be) | D51 | 1,089 | PPV =36.8 (34.0–39.7) | LABKA | Ghezala IB et al. Clin Epidemiol. 201273 |
| D69 | Chronic idiopathic thrombocytopenic purpura | 1996–2007 (IN/OUT;e A/Be) | D69 (>1 diagnosis >6 mo) | 439 | PPV =93.4 (90.7–95.4) | MR | Heden KEK et al. Clin Epidemiol. 200974 |
| E00–E90: Endocrine, nutritional and metabolic diseases | |||||||
| E10 | Diabetes mellitus | 1998–2007 (IN/OUT; A) | E10.0, E10.1, E10.9, E11.0, E11.1, E11.9 | 50 | PPV =96.0 (86.5–98.9) | DS | Thygesen SK et al. BMC Med Res Methodol. 201158 |
| 1999–2003 (IN/OUT;e A/Be) | E10–13, H36.0, O24, except O24.4 | n/a | PPV =64;f Se =97f | GP verification | Kristensen JK et al. Ugeskr Laeger. 200775 | ||
| 1992–2001 (IN/OUT/ED;e A/Be) | 249–250, E10–E11 (and/or a prescription for insulin or an oral antidiabetes drug) | 65 | PPV =96.9 (89.5–99.2) | MR, LABKA | Thomsen RW et al. Diabetes Care. 200476 | ||
| Diabetes in women | 1977–2006e (IN/OUT;e Ae) | 249; E10 | 40 | PPV =95.0 (83.5–98.6)e | MR | Atladottir HO et al. Pediatrics. 200977 | |
| Diabetes in children | 1996–2002 (A;e A/B) | E10–14 (age ≤15 y) | 1,479 | PPV =95.9 (94.8–96.8); NPV =100 (100–100);g Se =97.9 (97.1–98.6); Sp =100 (100–100)g | MR; Danish registry for child and adolescent diabetes | Svensson J et al. Ugeskr laeger. 200778 | |
| Type 1 diabetes mellitus | 1996–2002 (IN;e A/B) | E10–14 | 1,479 | PPV =94.3 (93.0–95.4); NPV =100 (100–100);g Se =98.0 (97.1–98.6); Sp =100 (100–100)g | MR; Danish registry for child and adolescent diabetes | Svensson J et al. Ugeskr laeger. 200778 | |
| 1987–1993 (IN; A/B) | 249 | 1,722 | PPV =96.3 (95.4–97.1); Se =91.0 (89.6–92.2) | MR; PR | Nielsen GL et al. J Med Syst. 199679 | ||
| E10.2 | Diabetes mellitus with chronic complications | 1998–2007 (IN/OUT; A) | E10.2–E10.8, E11.2–E11.8 | 50 | PPV =82.0 (69.2–90.2) | DS | Thygesen SK et al. BMC Med Res Methodol. 201158 |
| E22.0 | Acromegaly | 1991–2009 (IN/OUT/ED;e A/Be) | 253.00, 253.01; E22.0 | 275 | PPV =54.2 (48.3–60.0); PPVDep of endocrinology =66.7 (60.0–72.7) | MR | Dal J et al. Clin Epidemiol. 201480 |
| E282 | Polycystic ovarian syndrome | 1977–1988 (IN; A/B) | 256.90 (among women undergoing gynecological surgery) | 14 | PPV =85.7 (60.1–96.0); NPV =99.9 (99.8–100); Se =70.6 (46.9–86.7); Sp =100 (99.9–100) | DS | Kjaergaard J et al. J Clin Epidemiol. 200268 |
| E26.0 | Primary hyperaldosteronism | 1977–1981 (IN; A/B) | 255.00 (Conn’s syndrome) | 85 | PPV =22.4 (14.8–32.3) | MR | Lund JO et al. Ugeskr Laeger. 198681 |
| E41 | Undernutrition | 2002–2011 (IN;e A/Be) | E12, E41–44, E46–47, E64, Z03.8F (age ≥15 y) | 172 | PPVDefinite =11.1 (7.2–16.6) PPVDefinite/probable =70.9 (63.8–77.2) |
MR | Rasmussen NH et al. Clin Nutr. 201582 |
| E87 | Hyponatremia | 2006–2011 (IN; A/B) | E87.1, E87.1A, P74.2B | 5,850 | PPV =92.5 (91.8–93.1); NPV =86.2 (86.2–86.2); Se =1.8 (1.7–1.8); Sp =100 (100–100)g | LABKA | Holland-Bill L et al. BMJ Open. 201483 |
| F00–F99: Mental and behavioral disorders | |||||||
| F00 | Dementia | 1998–2007 (IN/OUT; A) | F00–F03, F05.1, G30 | 50 | PPV =98.0 (89.5–99.7) | DS | Thygesen SK et al. BMC Med Res Methodol. 201158 |
| 2003 (IN/OUT; A/B) | F00.0–F00.2, F00.9, G30.0–G30.1, G30.8–G30.9, F01.0–F01.3, F01.8–F01.9, F02.0, F03.9 | 197 | PPV =85.8 (80.2–90.0) overall, 81.0 (69.2–89.1) for Alzheimer dementia, 18.5 (8.2–36.7) for vascular dementia | MR; patient interview | Phung TKT et al. Dement Geriatr Cogn Disord. 200784 | ||
| G00–G99: Diseases of the nervous system | |||||||
| G12.2 | Amyotrophic lateral sclerosis | 1982–2009 (IN/OUT;e A/Be) | 348.0, G12.2 (age >19 y) | 173 | PPVdefinite =69.9 (62.7–76.3); PPVdefinite/probable =77.5 (70.7–83.1); PPVdefinite/probable/suspected =92.5 (87.6–95.6) | MR | Kioumourtzoglou MA et al. Amyotroph Lateral Scler Frontotemporal Degener. 201585 |
| G20 | Parkinson’s disease | 1996–2006 (IN/OUT; A) | 342, G20 | 1,040 | PPV =82.4 (80.0–84.6) | MR | Wermuth L et al. Dan Med J 201286 |
| 2002–2006 (IN/OUT;e Ae) | G20 (age ≥35 y) | 2,572 | PPV =91.5 (90.3–92.5) | PR | Rugbjerg K et al. BMJ. 200887 | ||
| Parkinson’s disease (women) | 1996–2009 (IN/OUT;e Ae) | G20e (neurology wards only) | 923 | PPV =80.5 (77.8–82.9) | MR | Greene N et al. Eur J Neurol. 201488 | |
| G35.9 | Multiple sclerosis treated at Department of Neurology or MS rehabilitation center | 1994–2004 (IN/OUT; A/B) | G35.9 | 4,185 | PPV =95.1 (94.3–95.8);f PPVneurol dep =96.3 (95.7–96.9); Se =92.8 (91.9–93.6);f Seneurol dep =86.9 (85.7–88.0) | Danish Multiple Sclerosis Registry | Mason K et al. Acta Neurol Scand. 201289 |
| G40 | Epilepsy | 1977–2002 (IN/OUT; A/Be) | 345, G40–41 | 188 | PPV =81.4 (75.2–86.3) | MR | Christensen J et al. Epilepsy Res. 200790 |
| G45 | Transient ischemic attack | 1998–1999 (IN;e A/Be) | G45 | 38 | PPV =57.9 (42.2–72.2) to 68.4 (52.5–80.9) | MR; DS; CT/MRI; autopsy reports; angiography reports | Krarup LH. Neuroepidemiology. 200791 |
| 1994–1999e (IN/OUT/ED; A/Be) | G45 | 134 | PPV =60.5 (52.0–68.3) | MR; DS | Johnsen SP et al. J Clin Epidemiol. 200292 | ||
| G81 | Hemiplegia | 1998–2007 (IN/OUT; A) | G81, G82 | 50 | PPV =100 (92.9–100) | DS | Thygesen SK et al. BMC Med Res Methodol. 201158 |
| H00–H95: Diseases of the eye, adnexa, ear, and mastoid process | |||||||
| H71 | Cholesteatoma | 1977–2007 (IN; A) | 387.09; H71, H95.0, Q16.4A + surgery codes (see these below under KDC) | 262 | PPV =89.3 (85.0–92.5); Se =89.3 (84.7–92.6) | Surgical records | Djurhuus BD et al. Dan Med Bull. 201093 |
| I00–I99: Diseases of the circulatory system | |||||||
| I10.9 | Essential hypertension in males | 1977–2010 (IN/OUT; A/B) | 400–404; I10–I15 | 524 | PPV =88.2 (85.4–90.9) | PR | Schmidt M et al. BMJ Open. 201394 |
| Essential hypertension | 1983–1990 (IN; A) | 401.99 | 310 | PPV =40 (26–55) to 60 (49–70)f | MR | Nielsen HW et al. Ugeskr Læger. 199695 | |
| I20.0 | Acute coronary syndrome | 1993–2003 (IN/OUT/ED; A/Be) | 410, 427.27; I20.0, I21, I46 | 1,558 | PPVIN/OUT/ED =65.5 (63.1–67.9); PPVIN =80.1 (77.7–82.3) | MR; DS; blood tests, ECG | Joensen AM et al. J Clin Epidemiol. 200996 |
| I20.0 | Unstable angina | 1993–2003 (IN/OUT/ED; A/Be) | I20.0 | 444 | PPVIN/OUT/ED =27.5 (23.5–31.8); PPVIN =42.0 (36.0–48.0) | MR; DS; blood tests, ECG | Joensen AM et al. J Clin Epidemiol. 200996 |
| I21 | Acute myocardial infarction | 1996–2009 (IN;e A) | I21 | 148 | PPV =100 (97.5–100) | MR | Coloma PM et al. BMJ Open. 201397 |
| 1998–2007 (IN/OUT; A) | I21, I22, I23 | 50 | PPV =98.0 (89.5–99.7) | DS | Thygesen SK et al. BMC Med Res Methodol. 201158 | ||
| 1993–2003 (IN/OUT/ED; A/Be) | 410; I21 | 1,072 | PPVIN/OUT/ED =81.9 (79.5–84.1); PPVIN; A/B =92.4 (90.4–93.9); PPVIN; A =94.4 (92.6–95.7) | MR; DS; blood tests, ECG | Joensen AM et al. J Clin Epidemiol. 200996,98 | ||
| 1982–1991 (IN; A/B) | 410, 427.24, 427.27, 427.91, 427.97 | 5,022 | PPVA =94.3 (93.6–94.9); PPVA+B =93.4 (92.6–94.0); SeA =62.8 (61.7–64.0); SeA+B =69.5 (68.4–70.6) | DANMONICA definite or possible cases incl cardiac arrest | Madsen M et al. J Clin Epidemiol. 200399 | ||
| 1979–1980 (IN; A/B) | 410–414 | 527 | PPV =92.4 (89.8–94.4) | DS | Madsen M et al. Ugeskr laeger. 1990100 | ||
| I26 | PE | 1994–2006 (IN/OUT/ED; A/B) | 450.99; I26 | 353 | PPVAll =67.4 (62.4–72.1); PPVIN/OUT =82.1 (77.2–86.1); PPVED =29.6 (22.0–38.5); PPVA =87.0 (81.9–90.9) | MR; DS; blood tests; ultrasound; venography; echo; V-P lung scan; CT scan | Severinsen MT et al. J Clin Epidemiol. 2010101 |
| PE during pregnancy and postpartum | 1980–2001 (IN;e Ae) | 450.00–450.99; I26.0–I26.9 + (650–666; O80–84) | 22 | PPVpreg+postpartum =81.8 (59.7–94.8);f PPVpreg =63.6 (40.7–82.8)f | MR | Larsen TB et al. J Clin Epidemiol. 2005102 | |
| PE after stroke | 2003–2006 (IN; A/B) | I26 (after admission to stroke units and age ≥18 y) | 11 | PPV =90.9 (62.3–98.4); NPV =97.4 (95.8–98.4); Se =0.0 (0.0–32–4); Sp =100 (99.3–100) | MR | Ingeman A et al. Clin Epidemiol. 2010103 | |
| I46 | Cardiac arrest | 1993–2003 (IN/OUT/ED; A/Be) | 427.27; I46 | 42 | PPVIN/OUT/ED =50.0 (35.5–64.5); PPVIN =53.1 (36.5–69.1) | MR; DS; blood tests, ECG | Joensen AM et al. J Clin Epidemiol. 200996 |
| I48 | Atrial fibrillation or flutter | 1993–2009 (IN/OUT/ED; A/B) | 427.93, 427.94; I48 | 284 | PPVAll =92.3 (88.6–94.8); PPVIN/OUT =94.0 (90.5–96.3) (independent of diagnosis type and department specialty); PPVED =64.7 (41.3–82.7) | MR + heart rhythm documentation | Rix TA et al. Scand Cardiovasc J. 2012104 |
| 1980–2002 (n/a; n/a) | 427.93, 427.94; I48 | 174 | PPV =98.9 (95.9–99.7) | MR + heart rhythm documentation | Frost L et al. Am J Med. 2007105 | ||
| 1980–2002 (n/a; n/a) | 427.93, 427.94; I48 | 116 | PPV =96.6 (91.5–98.7) | MR + heart rhythm documentation | Frost L et al. Arch Intern Med. 2004106 | ||
| I48.9A | Atrial flutter | 1977–1999 (IN/OUT/ED; A/B) | 427.94; I48.9A | 108 | PPV =50.0 (40.7–59.3) | MR + heart rhythm documentation | Rix TA et al. Scand Cardiovasc J. 2012104 |
| I50 | Heart failure | 1998–2007 (IN/OUT; A) | I50, I11.0, I13.0, I13.2 | 50 | PPV =100 (92.9–100) | DS | Thygesen SK et al. BMC Med Res Methodol. 201158 |
| Heart failure at University Hospital cardiac care unit | 2005–2007 (IN/OUT; A/B) | I11.0, I13.0, I13.2, I42.0, I42.6–9, I50.0–I50.1, I50.9 | 758 | PPVOverall = 84.0 (81.3–86.5); PPFirst-time events = 77.9 (74.1–81.6)f | MR | Mard S et al. Clin Epidemiol. 2010107 | |
| 1998–1999 (IN; A/B) | I50 | 156 | PPV =80.8 (73.9–86.2); NPV =90.1 (88.9–91.2); Sp =98.9 (98.5–99.2); Se =29.4 (25.3–33.9) | Clinical examination | Kümler T et al. Eur J Heart Fail. 2008108 | ||
| I60–I69 | Cerebrovascular disease | 1998–2007 (IN/OUT; A) | I60–I69, G45–G46 | 50 | PPV =94.0 (83.8–97.9) | DS | Thygesen SK et al. BMC Med Res Methodol. 201158 |
| 1998–1999 (IN;e A/Be) | I60–I69, G45 | 236 | PPV =78.4 (72.7–83.2) to 80.1 (74.5–84.7) | MR; DS | Krarup LH et al. Neuroepidemiology. 200791 | ||
| 1994–1999e (IN/OUT/ED; A/Be) | I60–I69.8, G45 | 565 | PPV =68.5 (64.6–72.2) | MR; DS | Johnsen SP et al. J Clin Epidemiol. 200292 | ||
| I60–I64 | Stroke | 1980–2002 (n/a; A/B) | 430–434, 436; I60–I64 following a diagnosis of atrial fibrillation/flutter | 164 | PPV =97.0 (93.1–98.7) | MR | Frost L et al. Am J Med. 2007105 |
| 2010 (IN; A) | I61, I63–I64 admitted to neurologic wards | 46 | PPV =93.5 (82.5–97.8); NPV =71.8 (62.8–79.4); Se =58.1 (46.7–68.7); Sp =96.3 (89.8–98.8) | MR including MRI and CT scan (for PPV). Other neurologic disorders were included to assess Se, Sp, and NPV | Wildenschild K et al. Clin Epidemiol. 2013109 | ||
| 1998–1999 (IN;e A/Be) | I60–I64 | 164 | PPV =80.5 (73.8–85.8) to 86.0 (79.8–90.5) | MR; DS | Krarup LH et al. Neuroepidemiology. 200791 | ||
| 1994–1999e (IN/OUT/ED; A/Be) | I60–I64 | 377 | PPV =79.3 (74.9–83.1) | MR; DS | Johnsen SP et al. J Clin Epidemiol. 200292 | ||
| Stroke complications | 2003–2006 (IN; A/B) | J12–J18, N30.0, N30.8, N30.9, N10, L899, R297, EUHE, I82.9A-E, I26, K590 (after admission to stroke units and age ≥18 y) | 88 | PPV =76.1 (66.3–83.8); NPV =85.1 (83.9–86.1); Se =7.7 (5.8–10.3); Sp =99.5 (99.2–99.7) | MR | Ingeman A et al. Clin Epidemiol. 2010103 | |
| I60 | Subarachnoid hemorrhage | 1998–1999 (IN;e A/Be) | I61 | 3 | PPV =66.7 (20.8–93.9) | MR; DS | Krarup LH et al. Neuroepidemiology. 200791 |
| 1994–1999e (IN/OUT/ED; A/Be) | I61 | 29 | PPV =48.3 (31.4–65.6) | MR; DS | Johnsen SP et al. J Clin Epidemiol. 200292 | ||
| 1977–1995 (IN;e A/Be) | 430; I60 | 191 | PPVneurosurgery wards =93 (85–98);f PPVneurology wards =75 (60–87);f PPVnon-specialty wards =47 (36–59)f | MR; DS; autopsy reports | Gaist D et al. BMJ. 2000110 | ||
| I6I | Intracerebral hemorrhage | 1998–1999 (IN;e A/Be) | I60 | 23 | PPV =73.9 (53.5–87.5) | MR; DS | Krarup LH et al. Neuroepidemiology. 200791 |
| 1994–1999e (IN/OUT/ED; A/Be) | I60 | 35 | PPV =65.7 (49.2–79.2) | MR; DS | Johnsen SP et al. J Clin Epidemiol. 200292 | ||
| I63 | Ischemic stroke | 1998–1999 (IN;e A/Be) | I63 | 33 | PPV =97.0 (84.7–99.5) to 100 (89.6–100) | MR; DS | Krarup LH et al. Neuroepidemiology. 200791 |
| 1994–1999e (IN/OUT/ED; A/Be) | I63 | 113 | PPV =87.6 (80.3–92.5) | MR; DS | Johnsen SP et al. J Clin Epidemiol. 200292 | ||
| Pediatric arterial thrombosis (0–18 y) | 1994–2006 (IN/OUT/ED;e A/B) | I63–I64, H34.1–H34.2, I74, N28.0A, N28.0D, I21 | 472 | PPVall =53.6 (49.1–58.1); PPVED =7.3 (2.5–19.4); PPVward =58.0 (53.3–62.6); PPVneonates =75.3 (64.9–83.4) | MR; lab tests; ECG; radiology reports | Tuckuviene R et al. Clin Epidemiol. 2010111 | |
| I64 | Unspecified stroke | 1998–1999 (IN;e A/Be) | I64 | 105 | PPV =72.4 (63.2–80.0) to 80.0 (71.4–86.5) for unspecified stroke confirmed as being any stroke | MR; DS | Krarup LH et al. Neuroepidemiology. 200791 |
| 1994–1999e (IN/OUT/ED; A/Be) | I64 | 200 | PPV =76.0 (69.6–81.4) for unspecified stroke confirmed as being any stroke | MR; DS | Johnsen SP et al. J Clin Epidemiol. 200292 | ||
| I70 | Peripheral vascular disease | 1998–2007 (IN/OUT; A) | I70–I74, I77 | 50 | PPV =100 (92.9–100) | DS | Thygesen SK et al. BMC Med Res Methodol. 201158 |
| I80.0 | Superficial thrombophlebitis during pregnancy/d postpartum | 1980–2001 (IN;e Ae) | 451.01, 451.91; I800 + (650–666; O80–84) | 125 | PPVpreg+postpartum =89.6 (84.3–95.0);f PPVpreg =88.0 (81.0–82.8)f | MR | Larsen TB et al. J Clin Epidemiol. 2005102 |
| I80.1–3 | DVT | 1994–2006 (IN/OUT/ED; A/B) | 451.00, 451.08, 451.09, 451.99; I80.1–I80.9 | 742 | PPVAll =54.6 (51.0–58.1); PPVIN/OUT =71.3 (67.4–74.9); PPVED =31.9 (27.1–37.0); PPVA =72.4 (68.2–76.2) | MR; DS; blood tests; ultrasound; venography; echo; V-P lung scan; CT scan | Severinsen MT et al. J Clin Epidemiol. 2010101 |
| DVT during pregnancy and postpartum | 1980–2001 (IN;e Ae) | 451.00, 451.08–451.09, 451.90, 451.92, 451.99; I80.1–I80.9 + (650–666; O80–84) | 153 | PPVpreg+postpartum =86.3 (79.8–91.3);f PPVpreg =74.5 (66.8–81.2)f | MR | Larsen TB et al. J Clin Epidemiol. 2005102 | |
| DVT after stroke | 2003–2006 (IN; A/B) | I82.9 (after admission to stroke units and age ≥18 y) | 8 | PPV =87.5 (52.9–97.8); NPV =97.1 (95.4–98.2); Se =16.7 (3.0–56.4); Sp =100 (99.3–100) | MR | Ingeman A et al. Clin Epidemiol. 2010103 | |
| I80.1–3+ I26 | VTE | 1994–2006 (IN/OUT/ED; A/B) | 450.99, 451.00, 451.08, 451.09, 451.99; I26, I80.1–I80.9 | 1,100 | PPVAll =58.5 (55.5–61.3); PPVIN/OUT =75.0 (71.9–77.8); PPVED =31.3 (27.2–35.7); PPVA =77.0 (73.7–80.0) | MR; DS; blood tests; ultrasound; venography; echo; V-P lung scan; CT scan | Severinsen MT et al. J Clin Epidemiol. 2010101 |
| 2004–2012 (IN/OUT; A/B) | I80.1–3, I26 + AC prescription ≤30 d after | 20 | PPV =90.0 (69.9–97.2) | MR | Schmidt M et al. J Thromb Haemost. 2014112 | ||
| Pediatric VTE (0–18 y) | 1994–2006 (IN/OUT/ED;e A/B) | I67.6, I63.6, G0.8, H34.8, I26, I80.1–I80.9, I81–I82, O22.5A, O87.3, O22.3, O22.8–O22.9, O87A–O87F, O87.1 | 640 | PPVall =53.9 (50.0–57.7); PPVED =7.4 (4.1–13.1); PPVward =66.3 (62.1–70.3); PPVneonates =82.4 (66.5–91.7) | MR | Tuckuviene R et al. Clin Epidemiol. 2010111 | |
| VTE in non-pregnant women 15–49 y | 2001–2009 (IN/OUT;e A/Be) | 438, 450, 451.00, 451.08, 451.99, 453.02; I26, I67.6, I80.1–I80.3,I82.2–I82.3, I82.8–I82.9 | 200 | PPV =76.0 (69.6–81.4); PPV+AC =99f | MR; ultrasound; phlebography; CT; scintigraphy | Lidegaard O et al. BMJ. 2011113 | |
| VTE during pregnancy and postpartum | 1980–2001 (IN;e Ae) | 450.00–450.99, 451.00–451.99; I26.0–I26.9, I80.0–I80.9 + (650–666, O80–84) | 304 | PPVpreg+postpartum =87.3 (83.0–90.9);f PPVpreg =79.3 (74.3–83.8)f | MR | Larsen TB et al. J Clin Epidemiol. 2005102 | |
| VTE recurrence | 2004–2012 (IN/OUT; A/B) | I80.1–3, I26 (>3 mo after first–time diagnosis) + ultrasound/CT scan during admission or AC prescription ≤30 d after | 90 | PPVIN/OUT, A/B, scan =27.5 (16.1–42.8); PPVIN/OUT, A/B, AC use =30.2 (18.6–45.1); PPVIN, A/B, scan =79.0 (56.7–91.5); PPVIN, A/B, AC use =56.5 (36.8–74.4) | MR | Schmidt M et al. J Thromb Haemost. 2014112 | |
| VTE in prostate cancer patients | 1995–2012 (IN/OUT; A/B) | I26, I80.1–3 (+ C61) | 115 | PPV =86.1 (78.6–91.3); NPV =98.3 (94.0–99.5); Se =98.0 (93.1–99.5); Sp =87.8 (81.1–92.3) | MR; VTE diagnostics | Drljevic A et al. Clin Epidemiol 201463 | |
| J00–J99: Diseases of the respiratory system | |||||||
| J12 | Respiratory syncytial virus infections | 1996–2003 (IN; A/B) | J12.1, J20.5, J21.0, B97.4 | 10,983 | PPV =92.1 (91.5–92.6); NPV =83.8 (83.4–94.2); Se =67.9 (67.1–68.6); Sp =96.6 (96.4–96.8) | MR; RSV Laboratory database | Stensballe LG et al. Scand J Infect Dis. 2005114 |
| J12 | Pneumonia after stroke | 2003–2006 (IN; A/B) | J12–J18 after (admission to stroke unit and age ≥18 y) | 14 | PPV =92.9 (68.5–98.7); NPV =63.3 (59.3–67.1); Se =6.0 (3.5–10.1); Sp =99.7 (98.5–100) | MR | Ingeman A et al. Clin Epidemiol. 2010103 |
| J40 | Chronic pulmonary disease | 1998–2007 (IN/OUT; A) | J40–J47, J60–J67, J68.4, J70.1, J70.3, J84.1, J92.0, J96.1, J98.2, J98.3 | 50 | PPV =100 (92.9–100) | DS | Thygesen SK et al. BMC Med Res Methodol. 201158 |
| J44 | COPD exacerbation | 2008 (IN; A/B) | J44A, J96A, J13A–J18A + J44B (age ≥30 y) | 1,581 | PPV =92.1 (90.7–93.3); NPVCOPD for related respiratory conditions =80.6 (78.5–82.5) | MR; 1,546 acute hospitalizations for J96 or J13–18 without J44 as B-diagnosis used to obtain NPV | Thomsen RW et al. Respir Med. 2011115 |
| J45 | Asthma history reported by male conscripts | 1977–2003 (IN/OUT/ED; A/Be) | 493; J45 | 925 | PPV =65.3 (62.2–68.3); NPV =96.5 (96.2–96.7); Se =44.5 (41.9–47.1); Sp =98.5 (98.3–98.6) | Conscription database | Jensen AO et al. Clin Epidemiol. 2010116 |
| J45 | Asthma in children | 2002 (IN; A) | J45, J46.9 (age 6–14 y) | 319 | PPV =84.6 (80.3–88.2); NPV =99.4 (99.1–99.6); Se =90.0 (86.1–92.9); Sp =99.4 (99.1–99.6) | MR; All acute admissions were assessed to yield Se, Sp, and NPV | Moth G et al. Acta Paediatr. 2007117 |
| J86.0 | Pleural empyema | 1995–2009 (IN; A/B) | 510; J86.0, J86.9 | 224 | PPV =90.6 (86.1–93.8) | MR; lab tests; radiology reports | Søgaard M et al. Clin Epidemiol 2011118 |
| K00–K93: Diseases of the digestive system | |||||||
| K25 | Ulcer disease | 1998–2007 (IN/OUT; A) | K22.1, K25–K28 | 50 | PPV =98.0 (89.5–99.7) | DS | Thygesen SK et al. BMC Med Res Methodol. 201158 |
| 1997–2001 n/a; n/a) | 531–534, K25–K28 | 200 | PPVOverall =84.5 (78.8–88.7); PPVbleeding ulcer =93.0 (84.6–97.0); PPVuncomplicated ulcer =72.7 (64.4–79.6) | MR | Lassen A et al. Am J Gastroenterol. 2006119 | ||
| K50 | Crohn’s disease | 1988–1992 (IN; A/Be) | 563.01 | 281 | PPV =97.2 (94.5–98.6); Se =94.4 (89.4–97.1) | MR and PD for PPV; PD for Se | Fonager K et al. Scand J Gastroenterol. 1996120 |
| K51 | Ulcerative colitis | 1988–1992 (IN; A/Be) | 563.19, 569.04 | 506 | PPV =90.3 (87.4–92.6); Se =93.7 (90.2–96.0) | MR and PD for PPV; PD for Se | Fonager K et al. Scand J Gastroenterol. 1996120 |
| K59.0 | Constipation after stroke | 2003–2006 (IN; A/B) | K59.0 (after admission to stroke units and age ≥18 y) | 7 | PPV =42.9 (15.8–75.0); NPV =84.7 (81.6–87.4); Se =3.9 (1.3–10.8); Sp =99.4 (98.2–99.8) | MR | Ingeman A et al. Clin Epidemiol. 2010103 |
| K70 | Mild liver disease | 1998–2007 (IN/OUT; A) | B18, K70.0–K70.3, K70.9, K71, K73–K74, K76.0 | 50 | PPV =100 (92.9–100) | DS | Thygesen SK et al. BMC Med Res Methodol. 201158 |
| K70 | Liver cirrhosis | 1985–1989 (IN; A/Be) | 571.09, 571.90–571.92, 571.99 | 198 | PPV =85.4 (79.8–89.6); Se =93.2 (85.9–96.8) | MR and PD for PPV; PD for Se only | Vestberg K. J Med Syst. 1997121 |
| K70.3 | Alcoholic cirrhosis | 1997–2005 (IN/OUT/ED;e A/B)e | 571.09; K70.3 (+ a liver biopsy during that hospital contact: SNOMED codes T56xxx) | 516 | PPV =77.7 (73.9–81.1) | PD | Jepsen P et al. BMC Gastroenterol. 2008122 |
| K72 | Moderate/severe liver disease | 1998–2007 (IN/OUT; A) | B15.0, B16.0, B16.2, B19.0, K70.4, K72, K76.6, I85 | 50 | PPV =100 (92.9–100) | DS | Thygesen SK et al. BMC Med Res Methodol. 201158 |
| K572–K579 | Diverticular disease | 1999–2008 (IN/OUT; A/Be) | K572–K579 | 100 | PPV =98.0 (93.0–99.5) | Discharge summary/outpatient notes | Erichsen R et al. Clin Exp Gastroenterol. 2010123 |
| K859 | Acute pancreatitis | 1981–2000 (IN;e A/Be) | 577.00–577.09; K85.9 | 99 | PPV1981–2000 =82 (72.8–88.9)f PPV1997–1999 =91 (83.0–96.0)f | MR | Floyd A et al. Scand J Gastroenterol. 2002124 |
| L00–L99: Diseases of the skin and subcutaneous tissue | |||||||
| L89.9 | Decubitus after stroke | 2003–2006 (IN; A/B) | L89.9 (after admission to stroke units and age ≥18 y) | 8 | PPV =50.0 (21.5–78.5); NPV =96.6 (94.7–97.8); Se =18.2 (5.1–47–7); Sp =99.5 (98.4–99.8) | MR | Ingeman A et al. Clin Epidemiol. 2010103 |
| M00–M99: Diseases of the musculoskeletal system and connective tissue | |||||||
| M00 | Septic arthritis after knee arthroscopy | 1998–2000 or 2003–2005 (IN; n/a) | M00, T81.4, T81.8–T81.9 (+ KNGA, KNGD, KNGE, KNGF, or KNGH) | 450 | Se =66.9 (59.2–73.8) | Danish Patient Insurance Association | Majholm B et al. Dan Med J. 2012125 |
| M05 | Rheumatoid arthritis (women) | 1977–2006e (IN/OUT;e Ae) | 712.19, 712.39, 712.59; M05, M06 | 40 | PPV =75.0 (59.8–85.8)e | MR | Atladottir HO et al. Pediatrics. 200977 |
| Rheumatoid arthritis | 1977–2001 (IN/OUT; A/B) | 712.19, 712.39, 712.59; M05–M06 (except M06.1) (age >15 y) | 217 | PPV =59.0 (52.3–65.3), higher for rheumatology departments and inpatient admissions; Se =26.4 (17.6–37.6) | PPV using MR/Se using MR-confirmed self-reported cases in the Danish Nationwide Twin Population cohort | Pedersen M et al. Eur J Epidemiol 2004126 | |
| M05 | Connective tissue disease | 1998–2007 (IN/OUT; A) | M05–M06, M08–M09, M30–M36, D86 | 50 | PPV =98.0 (89.5–100) | DS | Thygesen SK et al. BMC Med Res Methodol. 201158 |
| Connective tissue disease following breast implant | 1977–1993 (IN; A/B) | 712.09–712.39, 712.59, 716.09, 716.19, 734.00–734.09, 734.19, 734.90 | 35 | PPVDefinite =82.9 (67.3–91.9) | MR | Friis S et al. Ann Plast Surg. 1997127 | |
| M510 | Lumbar disc prolapse | 1990–1991 (IN; A) | 725.11 | 98 | PPV =90f | MR | Jensen MV et al. Ugeskr laeger. 1995128 |
| M87 | Osteonecrosis of the jaw in postmenopausal osteoporosis | 2005–2010 (IN/OUT;e A/Be) | K04.6, K10.2, K10.3, M87 | 60 | PPV =31.7 (21.3–44.2) | MR | Gammelager H et al. Clin Epidemiol. 2013129 |
| Osteonecrosis of the jaw among cancer patients | 2005–2009 (IN/OUT;e A/Be) | K04.6, K10.2–K10.3 (except K10.2E–F), M87 + prior C00–C97 (except C44) | 91 | PPV =19.8 (12.9–29.1) | MR | Gammelager H et al. Cancer Epidemiol. 2012130 | |
| Osteonecrosis of the jaw in patients with cancer diagnosed within 5 y | 2005–2010e (IN/OUT;e A/Be) | K04.6, K10.2, K10.3, M87 + prior C15–C29, C33–C43, C45–C97 (excl head and neck cancers and non-melanoma skin cancer) + departments of oral and maxillofacial surgeries | 197 | PPV =42.1 (35.5–49.1); Se =73.3 | MR | Ehrenstein V et al. Pharmacoepidemiol Drug Saf. 2014131 | |
| N00–N99: Diseases of the genitourinary system | |||||||
| N00 | Moderate to severe renal Disease | 1998–2007 (IN/OUT; A) | I12, I13, N00–N05, N07, N11, N14, N17–N19, Q61 | 50 | PPV =100 (92.9–100) | DS | Thygesen SK et al. BMC Med Res Methodol. 201158 |
| N30.0 | Urinary infection after stroke | 2003–2006 (IN; A/B) | N30.0, N30.8, N30.9, N10 (after admission to stroke units and age ≥18 y) | 39 | PPV =76.9 (61.7–87.4); NPV =70.9 (67.0–74.6); Se =14.3 (9.8–20.4); Sp =98.0 (96.1–99.0) | MR | Ingeman A et al. Clin Epidemiol. 2010103 |
| N80 | Endometriosis | 1977–1988 (IN; A/B) | 625.3 (among women undergoing gynecological surgery) | 427 | PPV =95.1 (92.6–96.8); NPV =89.3 (88.4–90.2); Se =45.8 (42.6–49.1); Sp =99.5 (99.2–99.7) | DS | Kjaergaard J et al. J Clin Epidemiol. 200268 |
| N830–N832 | Ovarian cysts | 1977–1988 (IN; A/B) | 615.2 | 601 | PPV =75.5 (72.0–78.8); NPV =87.2 (86.2–88.2); Se =45.1 (42.1–48.2); Sp =96.2 (95.6–96.8) | DS | Kjaergaard J et al. J Clin Epidemiol. 200268 |
| N91–N94 | Bleeding disorders | 1977–1988 (IN; A/B) | 626 (among women undergoing gynecological surgery) | 986 | PPV =93.9 (92.3–95.2); NPV =95.2 (94.5–95.8); Se =83.0 (80.7–85.1); Sp =98.4 (98.0–98.8) | DS | Kjaergaard J et al. J Clin Epidemiol. 200268 |
| O00–O99: Pregnancy, childbirth and puerperium | |||||||
| O021–03 | Abortion | 1984 (IN; A/Be) | 642, 644, and 631, 643, 645 if also registered in Register of Legally | 359 | PPV =46–69 for confirmation on four-digit level | DS | Schmidt L et al. Ugeskr laeger. 1989132 |
| Spontaneous abortion | 1980–2008 (IN/OUT/ED;e Ae) | 634.6, 645.1, 643.8, 643.9; O02.1A, O03 | 117 | PPVAll =97.4 (92.7–99.1) | DS | Lohse SR et al. Clin Epidemiol. 2010133 | |
| O04–06 | Provoked abortion | 1994 (IN;e A/Be) | O04–06 | 17,764 | PPV =93.5 (93.2–93.9); Se =97.0 (96.8–97.3) | Register of Legally Induced Abortions | Krebs L et al. Ugeskr laeger. 199732 |
| O139 | Gestational hypertension | 1998–2000 (IN/OUT; A/Be) | O13.9 | 3,039 | PPV =56.3 (33.2–76.9); NPV =97.3 (96.7–97.8); Se =10.0 (5.4–17.9); Sp =99.8 (99.5–99.9) | MR | Klemmensen ÅK et al. Am J Epidemiol. 2007134 |
| O139 | Hypertensive disorders of pregnancy | 1998–2000 (IN/OUT; A/Be) | O13.9–O14.1–O14.2, O14.9–O15.0 | 3,039 | PPV =88.8 (81.0–93.6); NPV =96.9 (96.2–97.5); Se =48.9 (41.6–56.2); Sp =99.6 (99.3–99.8) | MR | Klemmensen ÅK et al. Am J Epidemiol. 2007134 |
| 1982–1987 (IN; A/Be) | n/a | 112 | PPV =70;f NPV =98;f Se =75f | MR | Kristensen J et al. J Clin Epidemiol 1996135 | ||
| O14 | Preeclampsia | 1998–2000 (IN/OUT; A/Be) | O14.0–O14.2, O14.9–O15.0 | 3,039 | PPV =74.4 (64.0–82.6); NPV =99.1 (98.7–99.4); Se =69.3 (59.0–78.0); Sp =99.3 (98.9–99.5) | MR | Klemmensen ÅK et al. Am J Epidemiol. 2007134 |
| 2001 (IN; A/Be) | O13–14 | 39 | PPV =69.2 (53.6–81.4); NPV =98.6 (97.7–99.2); Se =64.3 (49.2–77.0); Sp =98.9 (98.1–99.4) | MR | Langhoff-Ross J et al. 2003136 | ||
| O24 | Gestational diabetes | 2001 (IN; A/Be) | O24 | 21 | PPV =100 (84.5–100); NPV =99.7 (99.2–99.9); Se =87.5 (69.0–95.7); Sp =100 (99.7–100) | MR | Langhoff-Ross J et al. 2003136 |
| O32 | Malpresentation of fetus | 2001 (IN; A/Be) | O32 | 37 | PPV =48.7 (33.5–64.1); NPV =99.3 (98.6–99.6); Se =69.2 (50.0–83.5); Sp =98.3 (97.3–98.9) | MR | Langhoff-Ross J et al. 2003136 |
| O342 | Previous cesarean section | 2001 (IN; A/Be) | O34.2, Z35.8E | 84 | PPV =90.5 (82.3–95.1); NPV =97.7 (96.6–98.5); Se =76.0 (66.8–83.3); Sp =99.2 (98.5–99.6) | MR | Langhoff-Ross J et al. 2003136 |
| O365 | Small for gestational age | 2001 (IN; A/Be) | O36.5 | 25 | PPV =56.0 (37.1–73.3); NPV =99.5 (98.8–99.8); Se =70.0 (48.1–85.5); Sp =99.0 (98.2–99.4) | MR | Langhoff-Ross J et al. 2003136 |
| O409 | Polyhydramnios | 1982–1987 (IN; A/Be) | n/a | 19 | PPV =74;f NPV =100;f Se =82f | MR | Kristensen J et al. J Clin Epidemiol 1996135 |
| O42 | Premature rupture of membranes | 2001 (IN; A/Be) | O42.3 | 50 | PPV =64.0 (50.1–75.9); NPV =98.5 (97.6–99.1); Se =66.7 (52.5–78.3); Sp =98.3 (97.4–98.9) | MR | Langhoff-Ross J et al. 2003136 |
| O44 | Placenta previa | 1982–1987 (IN; A/Be) | n/a | 53 | PPV =70;f NPV =99;f Se =68f | MR | Kristensen J et al. J Clin Epidemiol 1996135 |
| O45 | Abruptio placenta | 1982–1987 (IN; A/Be) | n/a | 172 | PPV =69;f NPV =97;f Se =70f | MR | Kristensen J et al. J Clin Epidemiol 1996135 |
| O489 | Prolonged pregnancy | 2001 (IN; A/Be) | O48.9 | 53 | PPV =67.9 (54.5–78.9); NPV =99.4 (98.7–99.7); Se =83.7 (70.0–91.9); Sp =98.4 (97.5–99.0) | MR | Langhoff-Ross J et al. 2003136 |
| O62 | Abnormalities of forces of labor | 2001 (IN; A/Be) | O62.2 | 317 | PPV =85.5 (81.2–88.9); NPV =88.2 (85.7–90.2); Se =73.8 (69.1–78.1); Sp =94.0 (92.0–95.4) | MR | Langhoff-Ross J et al. 2003136 |
| O641 | Obstructed labor due to breech presentation | 2001 (IN; A/Be) | O64.1, O32 | 46 | PPV =76.1 (62.1–86.1); NPV =99.4 (98.7–99.7); Se =83.3 (69.4–91.7); Sp =99.0 (98.2–99.4) | MR | Langhoff-Ross J et al. 2003136 |
| O654 | Obstructed labor due to fetopelvic disproportion | 2001 (IN; A/Be) | O65.4 | 21 | PPV =85.7 (65.4–95.0); NPV =98.6 (97.8–99.2); Se =54.6 (38.0–70.2); Sp =99.7 (99.2–99.9) | MR | Langhoff-Ross J et al. 2003136 |
| O68 | Fetal distress | 2001 (IN; A/Be) | O68 | 166 | PPV =63.3 (55.7–70.2); NPV =97.4 (96.2–98.2); Se =80.8 (73.2–86.6); Sp =93.9 (92.2–95.2) | MR | Langhoff-Ross J et al. 2003136 |
| O700 | First degree perineal laceration | 2001 (IN; A/Be) | O70.0 | 174 | PPV =50.6 (43.2–57.9); NPV =90.5 (88.4–92.2); Se =49.2 (41.9–56.4); Sp =90.9 (88.9–92.6) | MR | Langhoff-Ross J et al. 2003136 |
| O701 | Second degree perineal laceration | 2001 (IN; A/Be) | O70.1 | 91 | PPV =46.2 (36.3–56.3); NPV =96.3 (95.0–97.3); Se =52.5 (41.7–63.1); Sp =95.3 (93.9–96.4) | MR | Langhoff-Ross J et al. 2003136 |
| O710 | Rupture of uterus | 1980–1987 (IN; A/Be) | O71.0–O71.1 | 956 | PPV =13.5 (11.5–15.8) | MR | Devantier A et al. Ugeskr Læger 1991137 |
| O714 | Vaginal laceration | 2001 (IN; A/Be) | O71.4 | 56 | PPV =8.9 (3.9–19.3); NPV =99.7 (99.2–99.9); Se =62.5 (30.6–86.3); Sp =95.4 (94.1–96.5) | MR | Langhoff-Ross J et al. 2003136 |
| O72 | Postpartum hemorrhage | 2001 (IN; A/Be) | O72 | 57 | PPV =52.6 (39.9–65.0); NPV =98.6 (97.7–99.2); Se =66.7 (52.1–78.6); Sp =97.5 (96.4–98.3) | MR | Langhoff-Ross J et al. 2003136 |
| P00–P96: Certain conditions originating in the perinatal period | |||||||
| P22 | Infant respiratory distress syndrome | 1977–2008 (IN;e A/Be) | 776.19; P22.0 | 90 | PPVOverall =81.1 (71.8–87.9); PPVpreterm infants born <37 wks =89.2 (79.4–94.7) for | MR | Thygesen SK et al. Clin Epidemiol. 2013138 |
| P57.0 | Kernicterus | 1994–2003 (IN; A/Be) | P57.0, P57.7, P57.9 (+ gestational age ≥35 y) | 15 | PPV =40.0 (19.8–64.3) | MR | Maimburg RD et al. Acta Obstet Gynecol Scand. 2009139 |
| Q00–Q99: Congenital malformations, deformations and chromosomal abnormalities | |||||||
| Q20 | Congenital cardiac malformations | 2000–2008 (IN/OUT/ED;e A/Be) | Q20–25, except Q20.9, Q21.9, Q22.9, Q23.9, Q24.9, Q25.9 | 3,536 | PPV =98.4 (98.0–99.8) | MR | Agergaard P et al. Clin Epidemiol. 2011140 |
| 1994–2002 (IN/OUT;e A/Be) | Q20–26 | 418 | PPV =89.0 (85.6–91.7) | MR; echo, autopsy | Jepsen B et al. Int J Risk Saf Med. 2006141 | ||
| 1991–1994 (IN; A/Be) | 740–759; Q00–99 (except 755.69, 752.10–752.19, Q53, Q65) | 744 | PPV =88.2 (85.7–90.3); Se =89.9 (87.5–91.9) | MR; Medical Birth Registry; National Registry of Congenital Abnormalities | Larsen H et al. Scand J Public Health. 2003142 | ||
| Q53 | Cryptorchidism | 1995–2009 (n/a; A) | Q53 | 452 | PPV =80.3 (76.4–83.7) | MR | Jensen MS et al. J Urol. 2012143 |
| Q54 | Hypospadias | 1989–2003 (IN;e A/Be) | 752.20–752.29; Q54 | 43 | PPV =93.0 (81.4–97.6) | MR | Pedersen L et al. Int J Med Sci. 2006144 |
| Q96 | Turner syndrome | 1984–1993 (IN; A/B) | 310.54, 311.54, 312.54, 313.54, 314.54, 315.54, 759.50e | 237 | PPV =68.8 (62.6–74.3) | MR; Cytogenetic Central Register | Gravholt CH et al. J Clin Epidemiol. 1998145 |
| R00–R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | |||||||
| R29.7 | Falls after stroke | 2003–2006 (IN; A/B) | R29.7, EUHE (after admission to stroke units and age ≥18 y) | 1 | PPV =0.0 (0.0–79.4); NPV =84.5 (81.4–87.2); Se =0 (0–5.1); Sp =99.8 (98.9–100) | MR | Ingeman A et al. Clin Epidemiol. 2010103 |
| R56 | Febrile seizures | 1990–2001 (IN/OUT; A/Be) | 780.21; R56.0 | 249 | PPV =92.8 (88.8–95.4); NPV =98.6 (98.2–98.8); Se =71.5 (66.4–76.2); Sp =99.7 (99.6–99.8) | MR/telephone interviews | Vestergaard M et al. J Clin Epidemiol. 2006146 |
| R570 | Shock overall | 2005–2012 (IN; A/B) | R57.0–R57.2, A41.9A (+BFHC92, BFHC93 excl BFHC93E-H, BFHC95) | 158 | PPV =86.1 (79.8–90.6); PPV+ Inotrope/vasopressor =93.1 (84.8–97.0) | MR | Lauridsen MD et al. BMC Med Res Methodol. 2015147 |
| R570 | Cardiogenic shock | 2005–2012 (IN; A/B) | R570 (+ BFHC92, BFHC93 excl BFHC93E-H, BFHC95) | 46 | PPV =93.5 (82.5–97.8); PPV+ Inotrope/vasopressor =96.0 (80.5–99.3) | MR | Lauridsen MD et al. BMC Med Res Methodol. 2015147 |
| R571 | Hypovolemic shock | 2005–2012 (IN; A/B) | R571 (+ BFHC92, BFHC93 excl BFHC93E-H, BFHC95) | 34 | PPV =70.6 (53.8–83.2); PPV+ Inotrope/vasopressor =69.2 (42.4–87.3) | MR | Lauridsen MD et al. BMC Med Res Methodol. 2015147 |
| R572 | Septic shock | 2005–2012 (IN; A/B) | R572, A41.9A (+ BFHC92, BFHC93 excl BFHC93E-H, BFHC95) | 78 | PPV =69.2 (58.3–78.4); PPV+ Inotrope/vasopressor =82.4 (66.5–91.7) | MR | Lauridsen MD et al. BMC Med Res Methodol. 2015147 |
| S00–T98: Injury, poisoning and certain other consequences of external causes | |||||||
| S02 | Head injury | 1982–1985e (IN; n/a)e | 800–803, 850–854e | .50e | PPV =90f | MR | Sørensen HT et al. Ugeskr Laeger. 1987148 |
| S73 | Traumatic hip dislocation | 1989–1990 (IN; n/a) | 835.99 | 755 | PPV =16.0 (13.6–18.8) | MR; X-rays | Hougaard K et al. Ugeskr Laeger 1992149 |
| T634F | Anaphylactic shock after bee sting | 1973–1985 (IN; A/Be) | 999.49 | n/a | Se =60.0 (38.7–78.1) | MR | Sørensen HT et al. Allergy. 1989150 |
| T84.5 | Periprosthetic hip joint infection | 2003–2008 (IN; A/Be) | T84.5 + hip-specific NCSP code + departments of orthopedic surgery. Infection-specific surgery: KNFS19, KNFS49, KNFU89, KNFW69 | 283 | PPV =84.8 (80.2–88.5); PPV+ Infection-specific surgical code =86.1 (80.5–90.3) | MR | Lange J et al. Hip Int. 2015151 |
| Z00–Z99: factors influencing health status and contact with health services | |||||||
| Z131 | Glucose tolerance test | 2001 (IN; A/Be) | Z13.1 | 111 | PPV =57.7 (48.4–66.4); NPV =94.8 (93.2–96.0); Se =54.7 (45.7–63.4); Sp =95.4 (93.9–96.5) | MR | Langhoff-Ross et al. 2003136 |
| Z358D | High-risk pregnancy due to previous complicated pregnancy/birth | 2001 (IN; A/Be) | Z35.8D | 29 | PPV =34.5 (19.9–52.7); NPV =97.5 (96.5–98.3); Se =27.0 (15.4–43.0); Sp =98.3 (97.3–98.9) | MR | Langhoff-Ross et al. 2003136 |
| Z358E | High-risk pregnancy due to previous cesarean section | 2001 (IN; A/Be) | Z35.8E | 77 | PPV =88.3 (79.3–93.7); NPV =97.3 (96.1–98.1); Se =70.1 (60.4–78.3); Sp =99.1 (98.4–99.5) | MR | Langhoff-Ross et al. 2003136 |
| Other conditions | |||||||
| Charlson Comorbidity Index conditions | 1998–2007 (IN/OUT; A) | See individual diseases | 950 | PPV =98.0 (96.9–98.7) | DS | Thygesen SK et al. BMC Med Res Methodol. 201158 | |
| Treatments | |||||||
| Surgery (K) | |||||||
| KDC | Surgery for cholesteatoma | 1977–2007 (IN) | 20380–20700, 20990, KDC, KDD, KDE, KDFD30 (except KDCA10, KDCA20, KDCW00, KDEE, KDEE00) | 107 | PPV =98.1 (93.4–95.5) | Surgical records | Djurhuus et al. Dan Med Bull. 201093 |
| KHAD10 | Breast implant | 1977–1992 (IN) | 38500, 38540 | 2,576 | PPV =100 (99.9–100)g | MR | Friis S et al. Ann Plast Surg. 1997127 |
| 1977–1989 (IN; n/a) | 3854 | 71 | PPV =100 (94.9–100)g | MR | McLaughlin JK et al. J Natl Cancer Inst. 1995152 | ||
| KHAD00 | Breast augmentation | 1977–1989 (IN; n/a) | 3850 | 74 | PPV =94.6 (86.9–97.9) | MR | McLaughlin JK et al. J Natl Cancer Inst. 1995152 |
| KJAP | Intraperitoneal adhesiolysis | 1977–1988 (IN) | 40480 | 341 | PPV =95.9 (93.2–97.5); NPV =99;f Se =87.0 (83.2–90.0); Sp =100f | DS | Kjaergaard J et al. J Clin Epidemiol. 200268 |
| KJBC00 | Gastroesophageal antireflux operation | 1997–1999 (IN) | KJBC00, KJBC01 (age ≥18 y + admission >3 days or readmission or in-hospital death) | 243 | PPV =100 (98.4–100) | MR | Holte K et al. Ugeskr Laeger. 2001153 |
| KJEA | Appendectomy | 1977–1988 (IN) | 43000 | 899 | PPV =99.0 (98.1–99.5); NPV =100;f Se =98.5 (97.4–99.1); Sp =100f | DS | Kjaergaard J et al. J Clin Epidemiol. 200268 |
| KJKA2 | Cholecystectomy | 2004–2005 (IN) | KJKA2 | 1,361 | PPV =99.9 (99.6–100) | MR | Harboe KM et al. Int J Qual Health Care. 2009154 |
| KKFC10 | Orchiectomy in prostate cancer patients | 2002–2008 (IN) | KKFC10, KKFC13, KKFC15 | 50 | PPV =100 (92.9–100); NPV =100 (92.9–100) | MR | Jespersen CG et al. Clin Epidemiol. 2012155 |
| KKFH00 | Corrective surgery of cryptorchidism | 1995–2009 (IN) | KKFH00–KKFH01, KKFH10 | 249 | PPV =99.2 (97.1–99.8) | MR | Jensen MS et al. J Urol. 2012143 |
| KL | Operations for gynecological cancer | 1977–1988 (IN) | Hysterectomy, oophorectomy, partial resection of the ovaries (unspecified codes) | n/a (≈10,182) | PPV =95f | MR | Kjaergaard J et al. J Epidemiol Biostat. 200162 |
| KLAD00A | Unilateral ovarian resection | 1977–1988 (IN) | 60040 | 1,128 | PPV =96.2 (94.9–97.2); NPV =98;f Se =93.3 (91.7–94.6); Sp =99f | DS | Kjaergaard J et al. J Clin Epidemiol. 200268 |
| KLAD00B | Bilateral ovarian resection | 1977–1988 (IN) | 60060 | 195 | PPV =82.1 (76.1–86.8); NPV =100;f Se =91.4 (86.3–94.7); Sp =99f | DS | Kjaergaard J et al. J Clin Epidemiol. 200268 |
| KLAE1 | Unilateral oophorectomy | 1977–1988 (IN) | 60100 | 399 | PPV =90.5 (87.2–93.0); NPV =99;f Se =93.5 (90.6–95.6); Sp =99f | DS | Kjaergaard J et al. J Clin Epidemiol. 200268 |
| KLAE2 | Bilateral oophorectomy | 1977–1988 (IN) | 60120 | 87 | PPV =79.3 (69.7–86.5); NPV =100;f Se =79.3 (69.7–86.5); Sp =100f | DS | Kjaergaard J et al. J Clin Epidemiol. 200268 |
| KLAF0 | Unilateral salpingo-oophorectomy | 1977–1988 (IN) | 60320 | 925 | PPV =95.8 (94.3–96.9); NPV =98;f Se =90.4 (88.4–92.1); Sp =99f | DS | Kjaergaard J et al. J Clin Epidemiol. 200268 |
| KLAF1 | Bilateral salpingo-oophorectomy | 1977–1988 (IN) | 60300 | 534 | PPV =85.6 (82.4–88.3); NPV =99;f Se =89.6 (86.7–92.0); Sp =98f | DS | Kjaergaard J et al. J Clin Epidemiol. 200268 |
| KLCD | Hysterectomy | 1977–1988 (IN) | 61020 | 3,162 | PPV =99.1 (98.7–99.4); NPV =96;f Se =97.9 (97.3–98.3); Sp =98f | DS | Kjaergaard J et al. J Clin Epidemiol. 200268 |
| 1998–2000 (IN) | KLCC10, KLCC11, KLCC20, KLCD00, KLCD01, KLCD04, KLCD10, KLCD11, KLCD96, KLCD97, KLEF13e | 1,026 | PPV =99.8 (99.3–100) | DS | Møller C et al. Ugeskr laeger. 2002156 | ||
| KLCD10 | Total vaginal hysterectomy | 1977–1988 (IN) | 61040 | 157 | PPV =73.9 (66.5–80.1); NPV =100;f Se =93.6 (87.8–96.7); Sp =99f | DS | Kjaergaard J et al. J Clin Epidemiol. 200268 |
| KLCD11 | Supravaginal hysterectomy | 1977–1988 (IN) | 61000 | 184 | PPV =91.3 (86.3–94.6); NPV =100;f Se =88.0 (82.6–91.8); Sp =100f | DS | Kjaergaard J et al. J Clin Epidemiol. 200268 |
| KLCD30 | Radical hysterectomy | 1977–1988 (IN) | 61100 | 91 | PPV =90.1 (82.3–94.7); NPV =100;f Se =96.5 (90.1–98.8); Sp =100f | DS | Kjaergaard J et al. J Clin Epidemiol. 200268 |
| KLEF | Vaginal prolapse surgery | 1996–1998 (IN) | KLCD10, KLDC10, KLEF00, KLEF03, KLEF10, KLEF13, KLEF40, KLEF53, KLFE20 | 296 | PPV =69.3 (63.8–74.2) | MR | Ottesen M. Ugeskr Laeger 2009157 |
| KMAA00A | Amniocentesis | 2001 (IN) | KMAA00A | 32 | PPV =75.0 (57.9–86.8); NPV =96.8 (95.6–97.7); Se =40.7 (29.1–53.4); Sp =99.3 (98.5–99.6) | MR | Langhoff-Ross et al. 2003136 |
| KMAC00 | Labor induction with artificial rupture of membrane | 2001 (IN) | KMAC00 | 38 | PPV =55.3 (39.7–69.9); NPV =99.1 (98.3–99.5); Se =67.7 (50.1–81.4); Sp =98.5 (97.5–99.0) | MR | Langhoff-Ross et al. 2003136 |
| KMAC05 | Artificial rupture of membrane during labor | 2001 (IN) | KMAC05 | 98 | PPV =80.6 (71.7–87.2); NPV =79.9 (77.3–82.2); Se =27.6 (22.8–33.1); Sp =97.7 (96.5–98.6) | MR | Langhoff-Ross et al. 2003136 |
| KMAE | Vacuum extraction | 2001 (IN) | KMAE | 105 | PPV =97.1 (91.9–99.0); NPV =99.4 (98.7–99.7); Se =99.4 (88.4–97.4); Sp =99.7 (99.1–99.9) | MR | Langhoff-Ross et al. 2003136 |
| KMBA | Removal of placenta | 2001 (IN) | KMBA | 33 | PPV =81.8 (65.6–91.4); NPV =99.3 (98.6–99.6); Se =77.1 (61.0–87.9); Sp =99.5 (98.8–99.8) | MR | Langhoff-Ross et al. 2003136 |
| KMBC10 | Vaginal stitching | 2001 (IN) | KMBC10 | 87 | PPV =6.9 (3.2–14.2); NPV =99.8 (99.2–99.9); Se =75.0 (40.9–92.9); Sp =91.4 (89.4–93.0) | MR | Langhoff-Ross et al. 2003136 |
| KMBC30 | Perineal stitching (excl sphincter) | 2001 (IN) | KMBC30 | 242 | PPV =60.3 (54.1–66.3); NPV =85.0 (82.1–87.4); Se =57.9 (51.8–63.9); Sp =86.2 (83.4–88.6) | MR | Langhoff-Ross et al. 2003136 |
| KMBC33 | Perineal stitching (incl sphincter) | 2001 (IN) | KMBC33 | 25 | PPV =92.0 (75.0–97.8); NPV =98.5 (97.5–99.1); Se =62.2 (46.1–75.9); Sp =99.8 (99.2–99.9) | MR | Langhoff-Ross et al. 2003136 |
| KMCA | Cesarean section | 2001 (IN) | KMCA | 185 | PPV =97.8 (94.6–99.2); NPV =99.6 (98.9–99.8); Se =97.8 (94.6–99.2); Sp =99.6 (98.9–99.8) | MR | Langhoff-Ross et al. 2003136 |
| KN | Orthopedic surgery | 2004 (IN) | n/a | 554 | PPV =63.2 (59.1–67.1) | MR | Lass et al. Ugeskr laeger. 2006158 |
| KPBE2–KPBE3 | Upper limb embolectomy | 1990–2002 (IN) | 86823–86824, PBE20, PBE30 | 1,134 | PPV =97.3 (96.2–98.1) | MR | Andersen LV et al. Clin Epidemiol. 2009159 |
| KTMD00 | Episiotomy (incl stitching) | 2001 (IN) | KTMD00 | 130 | PPV =96.9 (92.4–98.8); NPV =99.6 (98.9–99.9); Se =97.7 (93.4–99.2); Sp =99.5 (98.8–99.8) | MR | Langhoff-Ross et al. 2003136 |
| Other treatments (B) | |||||||
| BAFA7 | Infiltration anesthesia | 2001 (IN; A/Be) | BAFA7 | 338 | PPV =60.1 (54.8–65.1); NPV =85.9 (82.9–88.4); Se =70.2 (64.7–75.2); Sp =79.5 (76.2–82.4) | MR | Langhoff-Ross et al. 2003136 |
| BAFA80 | Acupuncture | 2001 (IN; A/Be) | BAFA80 | 36 | PPV =75.0 (58.9–86.3); NPV =98.3 (97.3–98.9); Se =61.4 (46.6–74.3); Sp =99.1 (98.3–99.5) | MR | Langhoff-Ross et al. 2003136 |
| BAFA81 | Inhalation anesthesia with nitrous oxide | 2001 (IN; A/Be) | BAFA81 | 85 | PPV =76.5 (66.4–84.2); NPV =80.6 (77.9–83.0); Se =25.9 (20.9–31.7); Sp =97.5 (96.1–98.4) | MR | Langhoff-Ross et al. 2003136 |
| BAFA87 | Intracutaneous sterile water | 2001 (IN; A/Be) | BAFA87 | 20 | PPV =85.0 (64.0–94.8); NPV =96.0 (94.6–97.0); Se =29.3 (19.2–42.0); Sp =99.7 (99.1–99.9) | MR | Langhoff-Ross et al. 2003136 |
| BFHC92 | Inotropes/vasopressors in shock patients | 2005–2012 (IN) | BFHC92–BFHC93, BFHC95 (excl BFHC93E-H) (+ R570–R572, A41.9A) | 72 | PPV =88.9 (79.6–94.3) | MR | Lauridsen MD. BMC Med Res Methodol. 2015147 |
| BGDA | Mechanical ventilation in ICU patients | 2005–2010 (IN) | NABE/NABB + BGDA0 | 50 | PPV =100 (92.9–100) | MR | Blichert-Hansen et al. Clin Epidemiol. 2013160 |
| BJFD | Acute dialysis in ICU admitted patients | 2005–2010 (IN) | NABE/NABB + BJFD00/BJFD02 | 50 | PPV =98.0 (89.5–99.7) | MR | Blichert-Hansen et al. Clin Epidemiol. 2013160 |
| BKHD0 | Uterotonic drugs following birth | 2001 (IN; A/Be) | BKHD0 | 57 | PPV =12.3 (6.1–23.3); NPV =98.8 (97.9–99.3); Se =35.0 (18.1–56.7); Sp =95.5 (94.1–96.6) | MR | Langhoff-Ross et al. 2003136 |
| BKHD20 | Induction with prostaglandins | 2001 (IN; A/Be) | BKHD20 | 51 | PPV =98.0 (89.7–99.7); NPV =93.4 (91.8–94.7); Se =41.3 (33.0–50.2); Sp =99.9 (99.4–100) | MR | Langhoff-Ross et al. 2003136 |
| BKHD3 | Labor induction medication | 2001 (IN; A/Be) | BKHD3 | 298 | PPV =83.6 (78.9–87.3); NPV =92.5 (90.5–94.1); Se =80.0 (75.3–84.1); Sp =94.0 (92.2–95.4) | MR | Langhoff-Ross et al. 2003136 |
| BKQA0 | Bath | 2001 (IN; A/Be) | BKQA0 | 67 | PPV =85.1 (74.7–91.7); NPV =74.5 (71.6–77.1); Se =18.6 (14.7–23.4); Sp =98.6 (97.5–99.3) | MR | Langhoff-Ross et al. 2003136 |
| BWGC1 | Radiation therapy to the bone in patients with prostate (P) or breast (B) cancer | 2000–2005 | BWGC1 (+ C61.9/C50) | 16 P; 10 B | PPVP =75.0 (50.5–89.8); NPVP =83.3 (74.0–89.8); PPVB =60.0 (31.3–83.2); NPVB =95.6 (89.1–98.3); SeP =46.2 (28.8–64.5); SpP =94.6 (86.9–97.9); SeB =60.0 (31.3–83.2); SpB =95.6 (89.1–98.3) | MR | Jensen AØ et al. Clin Epidemiol. 200965 |
| BWHA | Chemotherapy for colorectal cancer | 2009–2010 | BWHA1–BWHA2, BOHJ19B | 35 | PPV =97.1 (85.5–99.5); NPV =93.3 (70.2–98.8); Se =97.1 (85.5–99.5); Sp =93.3 (70.2–98.8) | MR; hospital pharmacy production systems | Lund JL et al. Clin Epidemiol. 2013161 |
| BWHB40 | Bisphosphonate therapy in cancer patients | 2005–2009 | BWHB40 | 60 | PPV =98.3 (91.1–99.7) | MR | Nielsson MS et al. Clin Epidemiol 2012162 |
| BWHC | Gonadotropin-releasing hormone agonist in prostate cancer patients | 2002–2008 | BWHC | 100 | PPV =93.0 (86.3–96.6); NPV =94.0 (87.5–97.2); Se =93.9 (87.4–97.2); Sp =93.1 (86.4–96.6) | MR | Jespersen CG et al. Clin Epidemiol. 2012155 |
| ATC codes (M) | |||||||
| MJ06BB16 | Palivizumab | 1999–2010 | MJ06BB16 | 182 | PPVMR =91.7 (80.4–96.7); NPVMR =59.0 (53.3–64.5); SeMR =97.8 (20.5–33.9); SpMR =26.7 (94.4–99.1); PPVPR =90.7 (85.6–94.1); NPVPR =98.4 (97.9–98.9); SePR =79.7 (73.7–84.6); SpPR=99.4 (99.0–99.6) | MR; PR | Haerskjold A et al. Clin Epidemiol. 2015163 |
| Anesthesia and intensive care (N) | |||||||
| NAAC | General anesthesia | 2001 (IN) | NAAC | 20 | PPV =40.0 (21.9–61.3); NPV =95.9 (94.6–97.0); Se =15.1 (7.9–27.1); Sp =98.9 (98.1–99.4) | MR | Langhoff-Ross et al. 2003136 |
| NAAD0 | Epidural nerve block | 2001 (IN) | NAAD0 | 24 | PPV =75.0 (55.1–88.0); NPV =91.8 (89.9–93.3); Se =17.7 (11.5–26.2); Sp =99.4 (98.6–99.7) | MR | Langhoff-Ross et al. 2003136 |
| NAAD1 | Spinal anesthesia | 2001 (IN) | NAAD1 | 35 | PPV =77.1 (61.0–87.9); NPV =91.6 (89.8–93.1); Se =22.7 (16.1–31.0); Sp =99.2 (98.4–99.6) | MR | Langhoff-Ross et al. 2003136 |
| NAAD43 | Pudendal nerve block | 2001 (IN) | NAAD43 | 40 | PPV =70.0 (54.6–81.9); NPV =95.9 (94.4–97.0); Se =43.1(31.8–55.2); Sp =98.6 (97.6–99.2) | MR | Langhoff-Ross et al. 2003136 |
| NABB | Intensive care unit admission | 2005–2010 (IN) | NABB, NABE | 47 | PPV =87.2 (74.8–94.0) | MR | Blichert-Hansen et al. Clin Epidemiol. 2013160 |
| Examinations (U) | |||||||
| UXCC00A | Cardiac CT Angiography | 2008–2012 | UXCC00A | 289 | PPV =100 (98.7–100) | MR | Nielsen LH et al. Clin Epidemiol. 2014164 |
| UXUD88A | Fetal umbilical artery flow velocity measurement | 2001 (IN) | UXUD88A | 63 | PPV =77.8 (66.1–86.3); NPV =94.9 (93.4–96.1); Se =47.6 (38.2–57.1); Sp =98.6 (97.7–99.2) | MR | Langhoff-Ross et al. 2003136 |
Notes:
a
The ordering corresponds to the SKS browser, ie, ICD-10 for diagnoses and NOMESCO for surgery;
b
ICD codes without and with capital letters refer to ICD-8 and ICD-10 codes, respectively;
c
reflects the reviewed number of records in the DNPR (ie, the denominator in calculations of PPV). Among obstetric variables, we included only validation results based on >20 diagnoses;
d
confidence intervals were calculated using Wilson’s score method;
e
information not specified in validation papers, but confirmed through correspondence with authors. Unspecified and unconfirmed data are listed as not available (n/a);
f
recalculation of confidence intervals using Wilson’s score method not possible due to insufficient data;
g
confidence limit equals 100 due to rounding.
Abbreviations: A, primary diagnosis; AC, anticoagulant therapy; B, secondary diagnosis; COPD, chronic obstructive pulmonary disease; CT, computed tomography; d, day; DVT, deep venous thrombosis; DANMONICA, Danish Monitoring Trends and Determinants in Cardiovascular Disease project; DCR, Danish Cancer Registry; DNPR, Danish National Patient Registry; DS, discharge summaries; echo, echocardiography; ECG, electrocardiography; ED, emergency department; GP, general practitioner; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; ICD, International Classification of Diseases; ICU, intensive care unit; IN, inpatient contact; LABKA, Clinical Laboratory Information System Database; mo, month; MR, medical records; MRI, magnetic resonance imaging; MS, multiple sclerosis; n/a, not available; NPV, negative predictive value; OUT, outpatient contact; PD, Pathology Registry; PE, pulmonary embolism; PPV, positive predictive value; PR, Prescription Registry; PSA, prostate specific antigen; Se, study sample sensitivity; Sp, study sample specificity; ultrasound, ultrasonography; y, year(s); V-P, ventilation-perfusion; VTE, venous thromboembolism; NOMESCO, Nordic Medico-Statistical Committee; wks, weeks.